These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26535615)

  • 1. Docetaxel for the treatment of bladder cancer.
    Albany C; Sonpavde G
    Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
    Xue C; An X; Cao Y; Chen T; Yang W; Deng Y; Han H; Teng X; Zhou F; Shi Y
    Oncotarget; 2016 Sep; 7(39):63722-63729. PubMed ID: 27577082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
    Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
    Kassouf W; Luongo T; Brown G; Adam L; Dinney CP
    J Urol; 2006 Aug; 176(2):787-92. PubMed ID: 16813948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
    Jamy O; Sonpavde G
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
    Morales-Barrera R; Suárez C; Valverde C; Nuñez I; Maldonado X; Morote J; Carles J
    Clin Transl Oncol; 2014 Jan; 16(1):102-6. PubMed ID: 23606355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Patel R; Bock M; Polotti CF; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
    Sonpavde G; Bellmunt J; Rosenberg JE; Regazzi AM; Bajorin DF; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Pond GR
    Clin Genitourin Cancer; 2014 Dec; 12(6):395-8. PubMed ID: 25035282
    [No Abstract]   [Full Text] [Related]  

  • 11. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-of-the-art management of metastatic disease at initial presentation or recurrence.
    Calabrò F; Sternberg CN
    World J Urol; 2006 Nov; 24(5):543-56. PubMed ID: 17031652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic urothelial carcinoma.
    Lalani AA; Sonpavde GP
    Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
    McKiernan JM; Masson P; Murphy AM; Goetzl M; Olsson CA; Petrylak DP; Desai M; Benson MC
    J Clin Oncol; 2006 Jul; 24(19):3075-80. PubMed ID: 16809732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects and progress of immunotherapy for bladder cancer.
    Boegemann M; Aydin AM; Bagrodia A; Krabbe LM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1417-1431. PubMed ID: 28832261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.